ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2026
Diagnostic Performance of Six Insulin Resistance Indices for MAFLD Across BMI Categories in Type 2 Diabetes.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the diagnostic utility of six insulin resistance surrogate indices for metabolic dysfunction-associated fatty liver disease (MAFLD) across different body mass index (BMI) categories in patients with type 2 diabetes (T2DM). Methods: This single-center, cross-sectional study utilized a consecutive sampling method and was conducted at the Department of Endocrinology and Geriatrics, Huaian First People's Hospital (January 2018 to December 2022). Inclusion criteria were age ≥18 years and confirmed T2DM. A total of 2079 hospitalized adult patients meeting these criteria were initially screened. After applying exclusion criteria (including other diabetes types, secondary liver diseases, excessive alcohol consumption, low BMI, and incomplete data), 1205 patients with T2DM were enrolled and stratified by body mass index (BMI) into normal weight (n=429) and overweight/obese groups (n=776). MAFLD was diagnosed based on abdominal ultrasound, yielding 636 cases of MAFLD and 569 non-MAFLD controls. Six insulin resistance surrogate indices-homeostasis model assessment of insulin resistance (HOMA-IR), triglyceride-glucose index (TyG), triglyceride-glucose-body mass index (TyG-BMI), metabolic score for insulin resistance (METS-IR), triglyceride to high density lipoprotein cholesterol ratio (TG/HDL-C), and Chinese visceral adiposity index (CVAI)-were assessed for their diagnostic performance using receiver operating characteristic (ROC) analysis, DeLong's test, and decision curve analysis (DCA). Results: The overall prevalence of MAFLD was 52.78%, with rates of 34.03% in the normal weight group and 63.14% in the overweight/obese group. In the overweight/obese cohort, TyG-BMI demonstrated superior diagnostic accuracy (AUROC 0.769; optimal cut-off 240.503; sensitivity 76.37%, specificity 66.91%), significantly outperforming all other indices except for METS-IR, which showed comparable efficacy and could serve as an alternative. Among normal-weight individuals, TG/HDL-C exhibited the highest diagnostic performance (AUROC 0.763; optimal cut-off 2.908; sensitivity 70.00%, specificity 73.58%), which was significantly better than HOMA-IR and CVAI, but showed no significant difference compared with TyG, TyG-BMI, or METS-IR. DCA indicated that TyG-BMI consistently provided the greatest net clinical benefit, particularly within the high-risk threshold range (0.4-0.6), regardless of BMI category. Conclusion: TyG-BMI should be prioritized as the primary screening indicator for MAFLD in overweight and obese T2DM patients, with METS-IR as a valid alternative. In normal weight patients, TG/HDL-C demonstrates excellent clinical utility, with TyG-BMI serving as effective alternatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.